WO2020064977A1

WO2020064977A1 - Cosmetic formulation

Info

Publication number: WO2020064977A1
Application number: PCT/EP2019/076125
Authority: WO
Inventors: Marie DRAGO
Original assignee: Gallinee
Priority date: 2018-09-26
Filing date: 2019-09-26
Publication date: 2020-04-02
Also published as: FR3086170B1; EP3856131A1; FR3086170A1

Abstract

The invention relates to the technical field of cosmetic skin care and skin appendages, and more particularly to the field of cosmetic formulations for skin application. The invention relates to a cosmetic formulation, characterized in that it comprises at least one prebiotic and at least one postbiotic comprising acetic acid, or a salt thereof.

Description

COSMETIC FORMULATION

The invention relates to the technical field of cosmetic care of the skin and integuments, and more particularly the field of cosmetic formulations intended for skin application.

[0002] Prebiotics, probiotics and acetic acid are sometimes used in the field of cosmetics.

The term “prebiotic” means a food substance which is not digestible by humans and which selectively promotes the growth of certain bacteria of the probiotic type, thus affecting the host in a beneficial manner.

This definition was refined in 2004 with the following three characteristics: resistance to gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption;

- fermentation by the intestinal microflora;

- selective stimulation of the growth and / or activity of intestinal bacteria associated with health and well-being.

Prebiotics are often sugars, they are considered non-digestible fibers and can be classified according to their degree of polymerization into: monosaccharides;

0n there is for example tagatose, which is naturally present in small amounts in nature, and which can be produced from lactose by isomerization of galactose. Mainly recognized for its sweetening and anti-diabetic properties, it is also degraded by certain bacteria of the intestine of the genus Enterococcus and Lactobacillus.

disaccharides;

There is for example lactulose. Composed of a fructose and a galactose, it is a natural product derived from the treatment of milk by high temperature. Studies show prebiotic activity on Bifidus type bacteria (Bifidoba cterium), but it is marketed mainly for its qualities as an osmotic laxative.

- oligosaccharides;

The most common is inulin, an oligofructose polymer (abbreviated as FOS for Fructo-oligosaccharides) naturally present in nature. Depending on the degree of polymerization we can also speak of oligofructose.

There are also other oligosaccharides, such as transgalactooligosaccharides (TOS): mixture of oligosaccharides derived from lactose by enzymatic transglycosylation. Their precise content depends on the original saccharides and the enzymes used. Generally, these are tri-, tetra- or pentasaccharides: polydextrose, galactooligosaccharides (GOS) which are present naturally for example in colostrum and breast milk, or also alpha-glucan oligosaccharide.

Polysaccharides, such as glycogen.

Even if as seen above, the prebiotics are often sugars, it can also be peptides, we then speak of "peptide prebiotic". There are also prebiotics in the form of conjugated linoleic acids, polyunsaturated fatty acids, phenolic compounds, or even phytochemicals.

It is explicitly included in the definition of "prebiotic" mixtures comprising several prebiotics, as well as compositions comprising one or more prebiotics, such as for example the products of the ACTIBIOME ^® range. Thus, the range sold by the company CODIF under the trade name ACTIBIOME ^® , for example ACTIBIOME ^® PE (INCI: Water (and) seawater (and) glycerin (and) Laminaria digitata extract (and) Chlorella seen Ig a ris extract (and ) saccharide isomerate (and) phenoxyethanol (and) ethylhexylglycerin), or alternatively ACTIBIOME ^® G PA (Glycerin (and) Water (and) Seawater (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and) Saccharide isomerate (and) Phenethylalcohol ), are prebiotics. It is explicitly included in the definition of “prebiotic” extracts comprising at least one prebiotic, such as for example earth pear root juice (INCI: Polymnia sonchifolia root juice), rich in inulin.

The term “probiotic” is understood to mean microorganisms which, when administered in adequate amounts, confer a health benefit on their host. It is important to note that dead microorganisms can also have activity. In the context of the present application, within “probiotics”, a distinction will be made between “living probiotics” and “dead probiotics”. Dead probiotics can also be called "ghost" probiotics. In other words, the expressions "dead probiotic" and "ghost probiotic" are synonyms and these two expressions refer to the same probiotics. The probiotics can be bacteria (for example genera Lactobacillus and Bifidobacterium) or yeasts (for example Saccharomyces cerevisiae var. Boula rdii).

By "probiotic lysate" is meant the product of a lysis of probiotic (s).

The term “postbiotic” means bacterial products or metabolites of probiotic organisms which have biological activity on the host. For example, propionic acid, malic acid, citric acid, gluconic acid, lactic acid, butyric acid, hyaluronic acid or even acetic acid, are postbiotics. In the context of the present application, the extracts comprising at least one postbiotic are also considered to be postbiotics, for example the case of vinegar (including acetic acid). Acetic acid (CAS 64-19-7) is a carboxylic acid with the crude formula C2H4O2. Vinegar (CAS 90132-02-8) is an extract comprising acetic acid.

Acetic acid also exists in salified form, in particular in the form of sodium salt, potassium salt and calcium salt.

[00016] Acetic acid can be produced by the human body (for example from consumed ethanol).

Acetic acid is widely used in certain industrial fields as a solvent, it is also for example a food additive.

In the field of cosmetology, it can be used occasionally. It can in particular be used in hair products intended to be rinsed quickly.

The term “disaccharide” is used to designate a dimer formed from two oses (monosaccharides).

Called "oligosaccharide" an oligomer formed of a number n of oses

(monosaccharides), n varying between 3 and 10.

The term “polysaccharide” is used to designate a polymer formed of a number n of oses, n being strictly greater than 10.

The term “mass percentage” is used to refer to the mass ratio of a first compound relative to the total mass of a mixture of compounds (comprising the first compound) or composition, reduced to a percentage. For example, if 10 grams of a compound y are present in a mixture z having a total mass of 100 grams, then the mass percentage of y in z is 10%.

In the context of the present application, the term "approximately" preceding a numerical value means that the value can be modified by +/- 10%. In the particular case of a numerical value being an interval bound, the term "approximately" means that the lower bound can be reduced by 10% or the upper bound can be increased by 10%. It is also possible to delete the term "approximately" preceding a numerical value.

In the context of the present application, when it is specified that a value is included in an interval, the limits of the interval are included, and therefore said value can correspond to the high or low limit. For example, when a value A is between 1 and 2, it means: 1 <A <2.

In application FR3040624 filed in the name of Marie DRAGO, it is disclosed associations of prebiotics, probiotics and postbiotics. Acetic acid is not mentioned at all.

In application WO2016149687, there are disclosed cosmetic formulations comprising bacteria producing vinegar. There is a need to have cosmetic formulations comprising combinations of prebiotics and postbiotics, or even also comprising probiotics, capable of perfecting the cleaning of the skin, of providing care, of toning the skin, of soothe, balance, tighten skin pores, improve complexion, and allow increased hydration.

Surprisingly, it has been demonstrated by the applicant that cosmetic formulations having such properties could be obtained by means of the combination of at least one prebiotic and at least one postbiotic comprising acetic acid , or one of its salts.

Given the chemical and organoleptic characteristics of acetic acid, it is particularly surprising to note soothing and hydrating effects, when an association is made with at least one prebiotic. In addition, contrary to what one might expect, the smell of the formulations according to the invention is very pleasant, even without the use of any perfume, thanks to the combination of a prebiotic and acetic acid. .

Without wishing to be bound by any technical explanation, it is assumed that the prebiotic feeds commensal bacteria and has a negative effect on opportunistic bacteria (for example on Cutibacterium acnes, bacteria responsible for acne, or even on Staphylococcus aureus, bacteria responsible for eczema).

Bacterial selection is therefore carried out on the skin. This action is in synergy with that of acetic acid, which also has a role of bacterial selection.

The invention therefore relates to a cosmetic formulation, characterized in that it comprises:

- at least one prebiotic; and

- at least one postbiotic comprising acetic acid, or one of its salts.

The invention relates very particularly to a cosmetic formulation of the skin and the integuments, characterized in that it comprises:

- At least one prebiotic, the mass percentage of said at least one prebiotic being between approximately 0.1% and approximately 5% by mass relative to the total mass of said formulation; and

- at least one postbiotic comprising acetic acid, or one of its salts.

In one embodiment, the pH of said formulation is between 3 and 6.

In one embodiment, the pH of said formulation is between 3 and 6 (3 <pH <6). In one embodiment, the pH of said formulation is between 3.5 and 6.

In one embodiment, the pH of said formulation is between

3.5 and 6 (3.5 £ pH <6).

In one embodiment, the pH of said formulation is between 3.9 and 6.

In one embodiment, the pH of said formulation is between 3.9 and 6 (3.9 <pH <6).

In one embodiment, the pH of said formulation is strictly greater than 3.9 (pH> 3.9).

In one embodiment, the pH of said formulation is between 4 and 6.

In one embodiment, the pH of said formulation is between 4 and 6 (4 <pH <6).

In one embodiment, the pH of said formulation is between

4.5 and 5.5.

In one embodiment, the pH of said formulation is between 4.5 and 5.5 (4.5 <pH <5.5).

In one embodiment, the pH of said formulation is 4.5.

In one embodiment, the pH of said formulation is 5.

In one embodiment, the pH of said formulation is 5.5.

[00021] In one embodiment, said formulation is characterized in that said at least one prebiotic is a mixture comprising several prebiotics, such as compositions sold under the trade name ACTIBIOME ^®, e.g. ACTIBIOME ^® PE (INCI: Water (and) seawater (and) glycerin (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and) saccharide isomerate (and) phenoxyethanol (and) ethylhexylglycerin), or even ACTIBIOME ^® G PA (Glycerin (and) Water (and) Seawater (and) Laminaria digitate extract (and) Chlorella vulgaris extract (and) Saccharide isomerate (and) Phenethylalcohol).

In one embodiment, said formulation is characterized in that said at least one prebiotic is chosen from the group consisting of monosaccharides, disaccharides, oligosaccharides, isomaltooligosaccharides, and their mixtures.

In one embodiment, said formulation is characterized in that said at least one prebiotic is chosen from the group consisting of monosaccharides, disaccharides, oligosaccharides, and their mixtures.

In one embodiment, said formulation is characterized in that said at least one prebiotic is chosen from the group consisting of monosaccharides (such as tagadose), disaccharides (such as lactulose), oligosaccharides (such as inulin, transgalactooligosaccharides, polydextrose, galactooligosaccharides, b-fructooligosaccha wrinkles, a-glucooligosaccharides) polysaccharides (such as, for example, glycoogen), isomaltooligosaccharides (such as, for example, isomaltose) and mixtures thereof.

In one embodiment, said formulation is characterized in that said at least one prebiotic is chosen from the group comprising inulin

(marketed under the name INUTEC H25P®), the alphaglucane oligosaccharide

(sold under the name BIOECOLIA®), transgala cto-oligosaccharides (TOS), fructo-oligosacca wrinkles (FOS), galacto-5 oligosaccharides (GOS), and their mixtures.

In one embodiment, said formulation is characterized in that said at least one prebiotic is chosen from the group comprising inulin, alpha-glucan oligosaccharide, transgalacto-oligosaccharides (TOS), fructo-oligosaccarides (FOS) ), galacto-oligosaccharides 10 (GOS), and mixtures thereof.

In one embodiment, said formulation is characterized in that said at least one prebiotic is chosen from the group comprising inulin, alpha-glucan oligosaccharide, and their mixtures.

In one embodiment, said formulation is characterized in that said at least one prebiotic is a mixture of inulin and of oligosaccharide alphaglucan.

In one embodiment, said formulation is characterized in that it comprises at least 2 different prebiotics.

In one embodiment, said formulation is characterized in that it comprises at least 3 different prebiotics.

In one embodiment, said formulation is characterized in that it comprises at least 4 different prebiotics.

In one embodiment, said formulation is characterized in that said prebiotic is chosen from the group consisting of extracts of Lamina ria, extracts of Chlorella, and their mixtures.

In one embodiment, said formulation is characterized in that said prebiotic is an extract of Laminaria.

In one embodiment, said formulation is characterized in that said prebiotic is an extract of Laminaria chosen from the group consisting of Laminaria digitata, Laminaria abyssaiis, Laminaria apoda, Laminaria appressirhiza, Laminaria beivisii, Laminaria brasiiiensis, Laminaria bullata, Laminaria corda ta, Laminaria cornea, Laminaria cuneifolia, Laminaria discolor, Laminaria ephemera, Laminaria fariowii, Laminaria fissiiis, Laminaria flagellum, Laminaria gunneri, Laminaria himanthophylla, Laminaria hyperborea, Laminaria inclinatorhiza, Laminaria iamourouxii Laminaria leptopoda, Laminaria leptopoda, Laminaria longipes, Laminaria lyrata, Laminaria ochroleuca, Laminaria oiorhiza, Laminaria ophiura, Laminaria pallida, Laminaria paimata, Laminaria papyrina, Laminaria philippinensis, Laminaria platymeris, Laminaria pseudodaria repens, Laminaria rodriguezii, Laminaria ruprechtiana, Laminaria ruprechtii, Laminaria saccharoides, Laminaria sarniensis, Laminaria setchellii, Laminaria sinclairii, Laminaria solidungula, Laminaria turneri, Laminaria viridissima, Laminaria vittata, Laminaria yaminariaiaezaria Laminaria hyperborea, Laminaria longipes, Laminaria ochroleuca, Laminaria saccharina, Laminaria setchellii, Laminaria sinclairii, Laminaria solidungula, Laminaria yezoensis, and mixtures thereof.

In one embodiment, said formulation is characterized in that said prebiotic is an extract of Chloreiia.

In one embodiment, said formulation is characterized in that said prebiotic is an extract of Chloreiia chosen from the group consisting of Chloreiia vulgaris, Chloreiia acuminata, Chloreiia antarctica, Chloreiia bacteroidea, Chloreiia botryoides, Chloreiia chlorelloides, Chloreiia cladoniae, Chloreiia coelastroides, Chloreiia colonialis, Chloreiia conglomerata, Chloreiia desiccata, Chloreiia elongata, Chloreiia faginea, Chloreiia glorlosa, Chloreiia glucotropha, Chloreiia heliozoae, Chloreiia infusionum, Chloreiia kiettiloriaii, Chloreiia koettiitziai, Chloreiia koettiitia , Chloreiia peruviana, Chloreiia photophila, Chloreiia pituita, Chloreiia pulchelloides, Chloreiia rotunda, Chloreiia rubescens, Chloreiia rugosa, Chloreiia satina, Chloreiia singularis, Chloreiia sorokiniana, Chloreiia spaerckii, Chloreiia stoke, Chloreiia stoke belloidea Chloreiia vannielii, Chloreiia variabilis, Chloreiia variegata, Chloreiia volutis, Chloreiia xanthella, Chloreiia homosphaera, Chloreiia miniata, Chloreiia mirabilis, Chloreiia protothecoides Chloreiialore Chiaiialore Chiaiialore Chiaiiaia anitrata, Chloreiia lewinii, Chloreiia parvarotun, Chloreiia sphaerica, Chloreiia subsphaerica, and mixtures thereof.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of extracts of Laminaria and Chloreiia.

In one embodiment, said formulation is characterized in that said prebiotic is chosen from the group consisting of extracts of Laminaria digitata, extracts of Chloreiia vulgaris, and their mixtures.

In one embodiment, said formulation is characterized in that said prebiotic is an extract of Laminaria digitata. In one embodiment, said formulation is characterized in that said prebiotic is an extract of Chlorella vulgaris.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of extracts of Laminaria digitata and Chlorella vulgaris.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of extracts of Laminaria digitata and Chlorella vulgaris, and the mass ratio "extract of Laminaria digitata / extract of Chlorella vulgaris" is between 2 and 4.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of extracts of Laminaria digitata and Chlorella vulgaris, and the mass ratio "extract of Laminaria digitata / extract of Chlorella vulgaris" is between 2.5 and 3.5.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of extracts of Laminaria digitata and Chlorella vulgaris, and the mass ratio "extract of Laminaria digitata / extract of Chlorella vulgaris" is about 3.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture comprising at least 2 compounds chosen from the group of compounds having the following INCIs: seawater, glycerin, Laminaria digitata extract, Chlorella vulgaris extract, saccharide isomerate, phenoxyethanol, and ethylhexylglycerin.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture comprising at least 3 compounds chosen from the group of compounds having the following INCIs: seawater, glycerin, Laminaria digitata extract, Chlorella vulgaris extract, saccharide isomerate, phenoxyethanol, and ethylhexylglycerin.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture comprising at least 4 compounds chosen from the group of compounds having the following INCIs: seawater, glycerin, Laminaria digitata extract, Chlorella vulgaris extract, saccharide isomerate, phenoxyethanol, and ethylhexylglycerin.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture comprising at least 5 compounds chosen from the group of compounds having the following INCIs: seawater, glycerin, Laminaria digitata extract, Chlorella vulgaris extract, saccharide isomerate, phenoxyethanol, and ethylhexylglycerin.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture comprising at least 6 compounds chosen from the group of compounds having the following INCIs: seawater, glycerin, Laminaria digitata extract, Chlorella vulgaris extract, saccharide isomerate, phenoxyethanol, and ethylhexylglycerin. In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Water (and) seawater (and) glycerin (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) saccharide isomerate (and) phenoxyethanol (and) ethylhexylglycerin).

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Water (and) seawater (and) glycerin (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) saccharide isomerate (and) phenoxyethanol (and) ethylhexylglycerin), and in that the mass percentage of said prebiotic is between approximately 0.1% and approximately 5% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Water (and) seawater (and) glycerin (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) saccharide isomerate (and) phenoxyethanol (and) ethylhexylglycerin), and in that the mass percentage of said prebiotic is between approximately 0.5% and approximately

4.5% by mass relative to the total mass of the said formulation.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Water (and) seawater (and) glycerin (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) saccharide isomerate (and) phenoxyethanol (and) ethylhexylglycerin), and in that the mass percentage of said prebiotic is between approximately 1% and approximately 4% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Water (and) seawater (and) glycerin (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) saccharide isomerate (and) phenoxyethanol (and) ethylhexylglycerin), and in that the mass percentage of said prebiotic is between approximately 2% and approximately 4% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Water (and) seawater (and) glycerin (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) saccharide isomerate (and) phenoxyethanol (and) ethylhexylglycerin), and in that the mass percentage of said prebiotic is between approximately 2.5% and approximately

3.5% by mass relative to the total mass of the said formulation.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Water (and) seawater (and) glycerin (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) saccharide isomerate (and) phenoxyethanol (and) ethylhexylglycerin), and in that the mass percentage in said prebiotic is approximately 3% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture comprising at least 2 compounds chosen from the group of compounds having the following INCIs: Glycerin, Seawater, Laminaria digitata extract, Chlorella seen Ig laughed s extract, Saccharide isomerate, Phenethylalcohol.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture comprising at least 3 compounds chosen from the group of compounds having the following INCIs: Glycerin, Seawater, Laminaria digitata extract, Chlorella vulgaris extract, Saccharide isomerate, Phenethylalcohol.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture comprising at least 4 compounds chosen from the group of compounds having the following INCIs: Glycerin, Seawater, Laminaria digitata extract, Chlorella vulgaris extract, Saccharide isomerate, Phenethylalcohol.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture comprising at least 5 compounds chosen from the group of compounds having the following INCIs: Glycerin, Seawater, Laminaria digitata extract, Chlorella vulgaris extract, Saccharide isomerate, Phenethylalcohol.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Glycerin (and) Water (and) Seawater (and) Laminaria digitata extract (and) Chlorella vulgaris extra and ( and) Saccharide isomerate (and) Phenethylalcohol.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Glycerin (and) Water (and) Seawater (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) Saccharide isomerate (and) Phenethylalcohol, and in that the mass percentage of said prebiotic is between approximately 0.1% and approximately 5% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Glycerin (and) Water (and) Seawater (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) Saccharide isomerate (and) Phenethylalcohol, and in that the mass percentage of said prebiotic is between approximately 0.5% and approximately 4.5% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Glycerin (and) Water (and) Seawater (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) Saccharide isomerate (and) Phenethylalcohol, and in that the mass percentage in said prebiotic is between approximately 1% and approximately 4% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Glycerin (and) Water (and) Seawater (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) Saccharide isomerate (and) Phenethylalcohol, and in that the mass percentage of said prebiotic is between approximately 2% and approximately 4% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Glycerin (and) Water (and) Seawater (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) Saccharide isomerate (and) Phenethylalcohol, and in that the mass percentage of said prebiotic is between approximately 2.5% and approximately 3.5% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that said prebiotic is a mixture of compounds having for INCI: Glycerin (and) Water (and) Seawater (and) Laminaria digitata extract (and) Chlorella vulgaris extract (and ) Saccharide isomerate (and) Phenethylalcohol, and in that the mass percentage of said prebiotic is approximately 3% by mass relative to the total mass of said formulation

In one embodiment, said formulation is characterized in that the mass percentage of said at least one prebiotic is between approximately 0.1% and approximately 5% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that the mass percentage of said at least one prebiotic is between approximately 0.5% and approximately 4.5% by mass relative to the total mass of said formulation .

In one embodiment, said formulation is characterized in that the mass percentage of said at least one prebiotic is between approximately 1% and approximately 4% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that the mass percentage of said at least one prebiotic is between approximately 2% and approximately 4% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that the mass percentage of said at least one prebiotic is between approximately 2.5% and approximately 3.5% by mass relative to the total mass of said formulation .

In one embodiment, said formulation is characterized in that the mass percentage of said at least one prebiotic is approximately 3% by mass relative to the total mass of said formulation. In the context of this demand, it is particularly important to have a suitable prebiotic concentration.

In one embodiment, said formulation is characterized in that said at least one postbiotic comprising acetic acid, or one of its salts is chosen from the group consisting of acetic acid (CAS 64- 19-7) or one of its salts, vinegar (CAS 90132-02-8), and mixtures thereof.

In one embodiment, said formulation is characterized in that said at least one postbiotic comprising acetic acid, or one of its salts, is chosen from the group consisting of acetic acid or one of its salts, vinegar, and mixtures thereof.

In one embodiment, said formulation is characterized in that said at least one postbiotic comprising acetic acid, or one of its salts, is acetic acid, or one of its salts.

In one embodiment, said formulation is characterized in that said at least one postbiotic comprising acetic acid, or one of its salts, is acetic acid, or one of its chosen salts in the group consisting of sodium, potassium and calcium salts.

In one embodiment, said formulation is characterized in that said at least one postbiotic comprising a salt of acetic acid chosen from the group consisting of sodium, potassium and calcium salts.

In one embodiment, said formulation is characterized in that said at least one postbiotic comprising acetic acid, or one of its salts, is vinegar (CAS 90132-02-8).

In one embodiment, said formulation is characterized in that said at least one postbiotic comprising acetic acid is acetic acid or one of its salts, and the mass percentage of said acetic acid or l one of its salts is between approximately 0.001% and approximately 0.5% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that said at least one postbiotic comprising acetic acid is acetic acid or one of its salts, and the mass percentage of said acetic acid or l one of its salts is between approximately 0.001% and approximately 0.4% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that said at least one postbiotic comprising acetic acid is acetic acid or one of its salts, and the mass percentage of said acetic acid or l one of its salts is between approximately 0.001% and approximately 0.3% by mass relative to the total mass of said formulation. In one embodiment, said formulation is characterized in that said at least one postbiotic comprising acetic acid is acetic acid or one of its salts, and the mass percentage of said acetic acid or l one of its salts is between approximately 0.001% and approximately 0.1% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that said at least one postbiotic comprising acetic acid is acetic acid or one of its salts, and the mass percentage of said acetic acid or l one of its salts is between approximately 0.03% and approximately 0.07% by mass relative to the total mass of said formulation. In the context of the present application, it is particularly important to have a suitable postbiotic concentration.

Generally, when vinegar is used, then the quantities to be used will have to be adjusted according to the mass percentage of acetic acid (or one of its salts) in said vinegar.

Thus, for a vinegar comprising 10% acetic acid (or one of its salts), the mass percentage of said vinegar relative to the total mass of said formulation may be between approximately 0.01% and about 5%, preferably between about 0.01% and about 4%, preferably between about 0.01% and about 3%, preferably between about 0.01% and about 1%, preferably between about 0.3% and about 0.7%. More generally, when the amount of acetic acid to be added is E grams, and that vinegar comprises R% by mass of acetic acid, then the amount of vinegar to be added will be 100 / R x E grams.

In one embodiment, said formulation is characterized in that it also comprises at least one probiotic.

In one embodiment, said formulation is characterized in that said at least one probiotic is a living bacterium.

In one embodiment, said formulation is characterized in that said at least one probiotic is a bacterium of a genus chosen from the group consisting of the genus Ba ci II us, the genus Bifidobacterium and the genus Lactobacillus alive.

In one embodiment, said formulation is characterized in that said at least one probiotic is a bacterium of a genus chosen from the group consisting of the genus Ba ci II us and the genus Lactobacillus alive.

In one embodiment, said formulation is characterized in that said at least one probiotic is a bacteria of the living Bacillus genus.

In one embodiment, said formulation is characterized in that said at least one probiotic is a bacterium of the living Lactobacillus genus. In one embodiment, said formulation is characterized in that said at least one probiotic is a bacterium of the genus Bifidobacterium.

In one embodiment, said formulation is characterized in that it further comprises at least one probiotic being a living yeast.

In one embodiment, said formulation is characterized in that it further comprises at least one probiotic being a living yeast, for example Saccharomyces cerevisiae var. boulardii.

In one embodiment, said formulation is characterized in that said at least one probiotic is a dead bacterium.

In one embodiment, said formulation is characterized in that said at least one probiotic is a bacterium of a genus chosen from the group consisting of the genus Ba ci II us and the genus Lactobacillus dead.

In one embodiment, said formulation is characterized in that said at least one probiotic is a bacteria of the genus Bacillus dead.

In one embodiment, said formulation is characterized in that said at least one probiotic is a bacteria of the genus Lactobacillus dead.

In one embodiment, said formulation is characterized in that it further comprises at least one probiotic being a dead yeast.

In one embodiment, said formulation is characterized in that it further comprises at least one probiotic being a dead yeast, for example Saccharomyces cerevisiae var. boulardii).

In one embodiment, said formulation is characterized in that it also comprises at least one probiotic, and the mass percentage of said at least one probiotic is between approximately 0.01% and approximately 0.10% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that it also comprises at least one probiotic, and the mass percentage of said at least one probiotic is between approximately 0.01% and approximately 0.05% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that it also comprises at least one probiotic, and the mass percentage of said at least one probiotic is between approximately 0.02% and approximately 0.04% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that it also comprises at least one probiotic, and the mass percentage in said at least one probiotic is approximately 0.03% by mass, relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that it also comprises at least one lysate of probiotic.

In one embodiment, said formulation is characterized in that said probiotic lysate is a lysate of bacteria.

In one embodiment, said formulation is characterized in that said probiotic lysate is a lysate of bacteria of a genus chosen from the group consisting of the genus Bacillus and the genus Lactobacillus.

In one embodiment, said formulation is characterized in that said probiotic lysate is a lysate of bacteria of the Bacillus genus.

In one embodiment, said formulation is characterized in that said probiotic lysate is a lysate of bacteria of the Lactobacillus genus.

In one embodiment, said formulation is characterized in that said probiotic lysate is a yeast lysate.

In one embodiment, said formulation is characterized in that said probiotic lysate is a yeast lysate Saccharomyces cerevisiae var. boulardii.

In one embodiment, said formulation is characterized in that it also comprises at least one probiotic lysate, and the mass percentage of said at least one probiotic lysate is between approximately 1% and approximately 10% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that it further comprises at least one probiotic lysate, and the mass percentage of said at least one probiotic lysate is between approximately 1% and approximately 5% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that it also comprises at least one probiotic lysate, and the mass percentage of said at least one probiotic lysate is between approximately 2% and approximately 4% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that it further comprises at least one lysate of probiotic, and the mass percentage of said at least one lysate of probiotic is approximately 3% by mass, by relative to the total mass of said formulation.

In addition to the postbiotic comprising acetic acid, the formulation according to the invention may comprise one or more other postbiotic (s), hereinafter called “additional postbiotics”, the additional postbiotics cannot be chosen. in the group consisting of postbiotics comprising acetic acid. In one embodiment, said formulation is characterized in that it also comprises at least one additional post-diagnosis.

In one embodiment, said formulation is characterized in that it also comprises at least one additional postbiotic, chosen from the group consisting of propionic acid, malic acid, citric acid, gluconic acid, lactic acid, butyric acid, hyaluronic acid, and their isolated salts and isomers, and mixtures thereof.

In one embodiment, said formulation is characterized in that the at least one additional postbiotic is chosen from the group consisting of propionic acid, malic acid, citric acid, gluconic acid, lactic acid, butyric acid, and their isolated salts and isomers, and mixtures thereof.

In one embodiment, said formulation is characterized in that the at least one additional postbiotic is malic acid, or one of its salts. Malic acid is particularly preferred.

In one embodiment, said formulation is characterized in that the at least one additional postbiotic is citric acid, or one of its salts.

In one embodiment, said formulation is characterized in that the at least one additional postbiotic is gluconic acid, or one of its salts.

In one embodiment, said formulation is characterized in that the at least one additional postbiotic is butyric acid, or one of its salts.

In one embodiment, said formulation is characterized in that the at least one additional postbiotic is hyaluronic acid, or one of its salts.

In one embodiment, said formulation is characterized in that the at least one additional postbiotic is lactic acid, or one of its salts.

In one embodiment, said formulation is characterized in that the at least one additional postbiotic is lactic acid, or one of its salts, in a form chosen from the group consisting of forms D, L , and mixtures thereof in all proportions.

In one embodiment, said formulation is characterized in that the at least one additional postbiotic is lactic acid, or one of its salts, in D form.

In one embodiment, said formulation is characterized in that the at least one additional postbiotic is lactic acid, or one of its salts, in the form

L.

Form L is the preferred form, insofar as the latter is more advantageous with regard in particular to irritation. In one embodiment, said formulation is characterized in that the at least one additional postbiotic is lactic acid, or one of its salts, in the form of a mixture D and L

In one embodiment, said formulation is characterized in that the at least one additional postbiotic is lactic acid, or one of its salts, in the form of a racemic mixture (approximately 50% of D and about 50% of L).

In one embodiment, said formulation is ca acterized in that said lactic acid, or one of its salts, is combined with at least one amino acid.

In one embodiment, said formulation is characterized in that said lactic acid, or one of its salts, is combined with at least one amino acid, such as arginine.

In one embodiment, said formulation is characterized in that said lactic acid, or one of its salts, is combined with arginine, as for example in the commercial composition AH CA RE L65 ^® .

Indeed, the presence of arginine makes it possible not to sting the most sensitive skin.

In addition, the combination of lactic acid and arginine makes it possible to obtain a prolonged release of lactic acid, which is advantageous.

In one embodiment, said formulation is characterized in that the mass percentage of said at least one additional postbiotic is between approximately 0.1% and approximately 5% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that the mass percentage of said at least one additional postbiotic is between approximately 0.5% and approximately 4% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that the mass percentage of said at least one additional postbiotic is between approximately 0.6% and approximately 3% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that the mass percentage of said at least one additional postbiotic is between approximately 0.5% and approximately 0.8% by mass relative to the total mass of said formulation.

In one embodiment, said formulation is characterized in that it also comprises a cosmetically acceptable medium. In one embodiment, said formulation is characterized in that it also comprises conventional ingredients used in pharmaceutical and / or cosmetic formulation.

In one embodiment, said formulation is characterized in that it also comprises at least one compound chosen from the group of fatty substances, organic solvents, ionic or nonionic thickeners, softeners, antioxidants, opacifiers, stabilizers, emollients, silicones, alpha-hydroxy acids, defoamers, moisturizers, vitamins, fragrances, preservatives, surfactants, fillers, sequestrants, polymers, propellants, basifying agents, acidifying agents, and mixtures thereof.

In one embodiment, said formulation is characterized in that the fatty substances consist of an oil or a wax or their mixtures, and they also include fatty acids, fatty alcohols and fatty acid esters. The oils can be chosen from animal and vegetable oils.

In one embodiment, said formulation is characterized in that the thickeners are chosen in particular from crosslinked polyacrylic acids, Guar gums and modified or unmodified celluloses such as hydroxypropylated Guar gum, methylhydroxyethylcellulose and hydroxypropylmethylcellulose.

In one embodiment, said formulation is characterized in that it further comprises at least one active sunscreen in UV-A and / or UV-B, hydrophilic or lipophilic.

In one embodiment, said formulation also comprises at least one sun filter chosen from cinnamic derivatives, salicylic derivatives, camphor derivatives, triazine derivatives, benzophenone derivatives, dibenzoylmethane derivatives , derivatives of b, b'-diphenylacrylate, derivatives of p-aminobenzoic acid, polymer filters, silicone filters, and mixtures thereof.

In one embodiment, said formulation is characterized in that it also comprises at least one sun filter being a benzophenone derivative.

In one embodiment, said formulation is characterized in that it also comprises at least one sun filter being a derivative of benzophenone, for example avobenzone.

In one embodiment, said formulation is characterized in that it further comprises pigments or else nanopigments of metal oxides coated or not, such as for example titanium oxide nanopigments (amorphous or crystallized under rutile form and / or anatase) of iron, zinc, zirconium or cerium which are all known photoprotective agents acting by physical blocking (reflection and / or diffusion) of UV radiation. In one embodiment, said formulation is characterized in that it also comprises at least one coating agent, for example alumina and / or aluminum stearate.

In one embodiment, said formulation is characterized in that it does not comprise at least one compound chosen from the group consisting of silicones, dyes, mineral oils, parabens.

In one embodiment, said formulation is characterized in that it does not comprise silicone.

In one embodiment, said formulation is characterized in that it does not include a dye.

In one embodiment, said formulation is characterized in that it does not comprise mineral oil.

In one embodiment, said formulation is characterized in that it does not include parabens.

In the context of the present application, the term “liquid formulation” means a formulation which, at 20 ° C. and at atmospheric pressure:

- cannot be entered;

- deforms under the effect of its own weight (the formulation sinks);

- adapts to the shape of the container that contains it; and

- has a free surface which is always flat and horizontal at rest.

In one embodiment, said formulation is a liquid formulation.

In one embodiment, said formulation is an aqueous liquid formulation.

In the context of the present application, the term "solid formulation" is intended to mean a formulation which, at 20 ° C. and at atmospheric pressure:

- can be entered;

- does not deform under the effect of its own weight;

- has a free surface which has its own shape.

In one embodiment, said formulation is not a solid formulation.

In the context of the present application, liquid formulations are particularly preferred.

In one embodiment, said formulation is characterized in that it is in a form chosen from the group consisting of emulsions (simple or complex; O / W, W / O, O / W / O or W / O / W) such as a cream, a milk, a gel or a cream gel, powders, solid sticks, serums, and may optionally be packaged as an aerosol and be in the form of a foam, spray, or still aqueous lotion. In one embodiment, said formulation is in the form of a serum.

In one embodiment, said formulation is in the form of an aqueous lotion.

In one embodiment, said formulation is in the form of a cream, in particular O / W cream.

In one embodiment, said formulation is in the form of an aqueous gel.

In one embodiment, said formulation is a rinse-off hair formulation.

In one embodiment, said formulation is a non-rinsing hair formulation (not rinsed).

The invention also relates to the use of a formulation according to the invention, as a formulation chosen from the group consisting of care or hygiene formulations for the face and / or the body, moisturizing formulations, anti-aging formulations (anti-wrinkle and / or firming), depigmenting formulations, pro-pigmenting formulations, self-tanning formulations, slimming formulations, deodorant formulations, antiperspirant formulations, UV protection formulations, cleansing formulations, make-up removing formulations, biphasic make-up removing formulations, bath formulations, hair formulations (in particular a shampoo, a conditioner, a styling product, in particular for straightening), hair coloring formulations.

In one embodiment, said formulation is a topical formulation.

In one embodiment, said formulation is a topical formulation, that is to say which acts only at the place where it is applied.

In one embodiment, said formulation is used on the skin of the face in an individual with normal to oily skin on the face.

In one embodiment, said formulation is used on the skin of the face in an individual with sensitive skin on the face.

In one embodiment, said formulation is used on the skin of the face in an individual with non-sensitive skin on the face.

In one embodiment, said formulation is not suitable for the oral route.

The invention also relates to the use of a formulation according to the invention, as a formulation intended for application on the integuments (hair, hair, nails, teeth), or on the skin, or even on mucous. The invention also relates to the use of a formulation according to the invention, as a formulation intended for application on the integuments (hair, hair, nails, teeth).

The invention also relates to the use of a formulation according to the invention, as a formulation intended for application on a mucosa, for example on the oral mucosa.

The invention also relates to the use of a formulation according to the invention, as a formulation intended for application to the skin.

The invention also relates to the use of a formulation according to the invention, as a formulation intended for application to the hair.

The invention also relates to the use of a formulation according to the invention, as a formulation intended for application to the bristles.

The invention also relates to the use of a formulation according to the invention, as a formulation intended for application to the teeth.

The invention also relates to the use of a formulation according to the invention, as a formulation intended for application to the nails.

The invention also relates to the use of a formulation according to the invention, as a formulation intended for application on the integuments, for cosmetic use.

The invention also relates to the use of a formulation according to the invention, as a moisturizing formulation.

Description of the figures

Figure 1 illustrates the evolution of the hydration means (in arbitrary units; ordinate axis) of the treated site (point curve) and of the control site (cross curve) as a function of time (in hours; T = 0h, T = 1h, T = 2h and T = 3h; abscissa axis). It is deductible that the treated site has a significant gain in hydration, with a maximum gain at one hour after application.

Figure 2 illustrates the change in the percentage of variation in the degree of hydration of the treated site compared to the control site (degree of hydration in%) as a function of time (in hours). At T = 1 h, a statistically significant increase in the degree of hydration of the order of 28.8% is observed. At T = 2 h, a statistically significant increase in the degree of hydration of about 14.7% is observed. At T = 3 h, a statistically significant increase in the degree of hydration of the order is observed of 18.4%. Examples

Example 1: Formulation according to the invention

Table 1; Formulation according to the invention

The procedure for the preparation of the formulation is given below

Step 1: Prepare phase E and phase F. Check the homogeneity of the mixtures.

Step 2: In the mixer, introduce the ingredients of phase A with stirring. Check the homogeneity of the bulk. Step 3: Introduce phase B in the mixer with stirring. Check the homogeneity of the bulk.

Step 4: Introduce phase C in the mixer with stirring. Check the homogeneity of the bulk.

Step 5: Introduce phase D in the mixer with stirring. Check the homogeneity of the bulk.

Step 6: Introduce phase E in the mixer with stirring. Check the homogeneity of the bulk.

Step 7: Introduce phase F in the mixer with stirring until the desired pH is obtained. Check the pH and the homogeneity of the bulk. Make the QS (sufficient quantity) in water if necessary.

Step 8: Verification of the organoleptic characters.

Example 2: Evaluation of the hydrating potential of a cosmetic product after a single application: kinetics of hydration for 3 hours.

This example aims to assess the moisturizing potential of the formulation according to the invention of Example 1 during the three hours following its single application on the legs.

10 female adult volunteers, aged 18 to 70 years (average age 58 years) and having dry skin in the legs (corneometric values less than or equal to 50 arbitrary units AU), are included in the study.

The example is monocentric, open and comparative between Tx and T0, on the treated site.

[000207] It comprises:

- an initial assessment;

- a treatment period during which 0.07 ml of pure product was applied to a surface of 35 cm ² on the external surface of the legs (amount applied of 0.07 ml, ie 2pl / cm ² );

- an evaluation period lasting three hours by taking corneometric measurements (the measurements of the electrical capacity are carried out with a

Corneometer CM 825 (Courage + Khazaka electronic GmbH), the values of the electrical capacity are given in arbitrary units (u.a.) fixed by the device on a scale of 0 u.a. to 130 u.a. These values reflect the degree of hydration of the upper layers of the epidermis at a given time).

The measurements were carried out by the same person throughout the test.

The corneometric values measured at T = 0, T = 1 h, T = 2 h and T = 3 h at the control site are given below:

Table 2: Corneometric values expressed in UA (control site)

The corneometric values measured at T = 0, T = 1 h, T = 2 h and T = 3 h at the level of the treated site are given below:

Table 3: Corneometric values expressed in UA (treated site)

The hydration means and standard deviations of the treated and control sites with regard to skin hydration were treated by the Wilcoxon test for paired data. The results are given below:

Table 4: Wilcoxon test for paired data

It is confirmed that the differences observed are significant.

The percentages of variation of the degree of hydration at the different measurement times are given below:

Table 5: Percentages of variation of the degree of hydration at the different measurement times (T = 1h, T = 2h and T = 3h)

Furthermore, no manifestation of skin intolerance was detected. In summary, the cosmetic formulation according to the invention of Example 1 exhibited statistically significant hydrating activity, with in particular a maximum hydration gain of 28.8% one hour after application. Example 3: Evaluation of skin tolerance, perceived effectiveness and acceptability of a formulation according to the invention (formulation of Example 1)

The formulation according to the invention of Example 1 was tested on 3 panels of volunteers.

The formulation according to the invention of Example 1 was evaluated with regard to skin tolerance, perceived effectiveness and acceptability.

Example 3.1 (panel 1/3):

The criteria for including volunteers are as follows:

- woman, in good health, aged 18 to 70;

- person declaring to have normal to oily skin on the face

(100% of the panel)

- person declaring to have sensitive skin on the face (50% of the panel).

Tolerance test

The formulation according to the invention of Example 1 was applied with a cotton pad morning and evening to clean skin 2 times a day on the face, under dermatological control, for a period of 28 days. (from D0 to D28) with 38 volunteers.

The tolerance data are obtained on the one hand by the comparison of clinical signs rated by a dermatologist on D0 and D28 (dermatological symptomatology), the importance of the various clinical signs observed in the different areas is rated 0 ( absence of sign) to 10 (severe sign), and on the other hand by the collection of unpleasantness and feelings of discomfort due to the product during the 28 days of use (functional symptomatology).

The dermatological symptomatology data are presented below:

Table 6: Dermatological symptoms These data were processed with the Wilcoxon test, and the results are presented below:

Table 7: Results of the Wilcoxon test for comparing the clinical scores noted by the dermatologist at OJ and D28.

In conclusion, for the clinical signs of erythema, dryness, scaling and hyperkeratosis, no significant difference is observed, therefore the formulation according to the invention of Example 1 is well tolerated.

Regarding the functional symptomatology:

- 37/38 volunteers did not feel any inconvenience during the study, the individual functional tolerance of these 37 volunteers is considered to be “excellent”.

- 1/38 volunteer declared having felt tingling between the cheeks and the nose during certain applications. The tingling was moderate in intensity and lasted 2-3 minutes. For this volunteer, individual tolerance is considered to be "average".

The overall tolerance is then evaluated according to the dermatological symptomatology and the functional symptomatology on a 7-point scale ("excellent", "very good", "good", "fairly good", "moderate", " pretty bad "," bad ").

After 28 days of using the formulation according to the invention of Example 1, considering the dermatologist's observations and the comparative analyzes D28 / D0, good clinical tolerance has been demonstrated. Furthermore, the functional tolerance was very good. Overall, the tolerance of the product was very good during the 28 days of use.

[000228] Perceived effectiveness and acceptability test

The data are obtained by filling in a questionnaire on D28 by all of the volunteers with questions according to a 4-point scale ("strongly disagree", "rather disagree", " rather agree ”and“ totally agree ”). The results are given below:

Table 8: Responses to questionnaires In conclusion, the cosmetic formulation according to the invention has been highly appreciated. At the end of the study, 83% of the volunteers were satisfied with the formulation and 75% would buy it if it was on the market at a reasonable price.

Example 3.2 (panel 2/3):

The criteria for including volunteers are as follows:

- woman, in good health, aged 18 to 70;

- person declaring to have normal to oily skin on the face (100% of the panel);

- person declaring to have non-sensitive skin on the face (50% of the panel).

Tolerance test

The formulation according to the invention of Example 1 was applied with a cotton pad morning and evening to clean skin 2 times a day on the face, under dermatological control, for a period of 28 days. (from D0 to D28) with 18 volunteers.

The inclusion criteria are as follows:

The dermatological symptomatology data are presented below:

Table 9: Dermatological symptomatology

These data were processed with the Wilcoxon test, and the results are presented below:

Table 10: Results of the Wilcoxon test to compare the clinical scores noted by the dermatologist at OJ and D28.

In conclusion, for clinical signs of erythema, dryness, scaling and hyperkeratosis, no significant difference is observed, therefore the formulation according to the invention of Example 1 is well tolerated.

Regarding the functional symptomatology:

- 17/18 volunteers did not feel any inconvenience during the study, the individual functional tolerance of these 17 volunteers is considered to be “excellent”;

- 1/18 volunteer declared having felt tingling between the cheeks and the nose during certain applications. The tingling was moderate in intensity and lasted 2-3 minutes. For this volunteer, individual tolerance is considered to be "average".

After 28 days of using the formulation according to the invention of Example 1, considering the dermatologist's observations and the comparative analyzes D28 / D0, good clinical tolerance has been demonstrated. Furthermore, tolerance functional was very good. Overall, the tolerance of the product was very good during the 28 days of use.

[000244] Perceived effectiveness and acceptability test

The data are obtained by filling in a questionnaire on D28 by all of the volunteers with questions on a 4-point scale ("strongly disagree", "somewhat disagree", "somewhat agree ”and“ strongly agree ”).

The results are given below:

Table 11: Responses to questionnaires

In conclusion, the cosmetic formulation according to the invention has been highly appreciated. At the end of the study, 78% of the volunteers were satisfied with the formulation and 72% would buy it if it was on the market at a reasonable price. Example 3.3 (panel 3/3):

The criteria for including volunteers are as follows:

- woman, in good health, aged 18 to 70;

- person declaring to have normal to oily skin on the face;

- person declaring to have sensitive skin on the face

Tolerance test

The formulation according to the invention of Example 1 was applied with a cotton pad morning and evening to clean skin 2 times a day on the face, under dermatological control, for a period of 28 days (from D0 at D28) with 20 volunteers.

The tolerance data are obtained on the one hand by the comparison of clinical signs rated by a dermatologist on D0 and D28 (dermatological symptomatology), the importance of the various clinical signs observed in the different areas is rated 0 (absence of sign) to 10 (severe sign), and on the other hand by the collection of unpleasantness and feelings of discomfort due to the product during the 28 days of use (functional symptomatology).

[000251] The dermatological symptomatology data are presented below:

Table 12: Dermatological symptomatology

Table 13: Results of the Wilcoxon test for comparing the clinical scores noted by the dermatologist at OJ and D28.

In conclusion, for the clinical signs of erythema, dryness, scaling and hyperkeratosis no significant difference is observed, therefore the formulation according to the invention of Example 1 is well tolerated.

Regarding the functional symptomatology, 20/20 volunteers (the entire panel of 20 women) did not feel any inconvenience during the study, the individual functional tolerance of these 20 volunteers is considered to be "excellent" .

The overall tolerance is then evaluated according to the dermatological symptomatology and the functional symptomatology on a 7 point scale ("excellent", "very good", "good", "fairly good", "moderate", " pretty bad "," bad ").

After 28 days of using the formulation according to the invention of Example 1, considering the dermatologist's observations and the comparative analyzes D28 / D0, good clinical tolerance has been demonstrated. Furthermore, the functional tolerance was excellent. Overall, the tolerance of the product was excellent during the 28 days of use.

[000257] Perceived effectiveness and acceptability test

The data are obtained by filling in a questionnaire on D28 by all of the volunteers with questions on a 4-point scale ("strongly disagree", "somewhat disagree", "somewhat agree ”and“ strongly agree ”). The results are given below:

Table 14: Responses to questionnaires

In conclusion, the cosmetic formulation according to the invention has been much appreciated. At the end of the study, 86% of the volunteers were satisfied with the formulation and 77% would buy it if it was on the market at a reasonable price.

Claims

1. Cosmetic formulation, characterized in that it comprises:

at least one prebiotic; and

at least one postbiotic comprising acetic acid, or one of its salts.

2. Formulation according to claim 1, characterized in that the pH of said formulation is between 4 and 6.

3. Formulation according to any one of the preceding claims, characterized in that the mass percentage of said at least one prebiotic is between approximately 0.1% and approximately 5% by mass relative to the total mass of said formulation.

Formulation according to any one of the preceding claims, characterized in that the said at least one component comprising acetic acid, or one of its salts, is chosen from the group consisting of acetic acid or one of its salts, vinegar and their mixtures.

4. Formulation according to any one of the preceding claims, characterized in that the mass percentage of said at least one component comprising acetic acid, or one of its salts is between approximately 0.1% and approximately 5 % by mass relative to the total mass of said formulation.

5. Formulation according to any one of the preceding claims, characterized in that it also comprises at least one probiotic.